Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Immunotherapy|January 11, 2019
Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficienciesKenneth Paris, Elie Haddad, Michael Borte, et al.Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|September 17, 2024
fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety studyPeter Čižnár, Marion Roderick, Helen Schneiderova, et al.Journal of Clinical Immunology|September 2, 2016
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North AmericaDaniel Suez, Mark Stein, Sudhir Gupta, et al.Immunotherapy|July 4, 2019
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continentsDaniel Suez, Gergely Kriván, Stephen Jolles, et al.Immunotherapy|June 18, 2024
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization studyPauline M Ellerbroek, Leif G Hanitsch, Torsten Witte, et al.Nature Immunology|September 6, 2003
Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombinationKohsuke Imai, Geir Slupphaug, Wen-I Lee, et al.Journal of Clinical Immunology|August 16, 2015
A Novel Targeted Screening Tool for Hypogammaglobulinemia: Measurement of Serum Immunoglobulin (IgG, IgM, IgA) Levels from Dried Blood Spots (Ig-DBS Assay)Leman Yel, Christopher J Rabbat, Charlotte Cunningham-Rundles, et al.Journal of Clinical Immunology|March 14, 2025
Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency DiseasesNiraj C Patel, Jolan E Walter, Richard L Wasserman, et al.Journal of Clinical Immunology|May 26, 2016
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary ImmunodeficiencyRichard L Wasserman, Isaac Melamed, Mark R Stein, et al.Immunotherapy Advances|March 21, 2024
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label studyHirokazu Kanegane, Akifumi Endo, Satoshi Okada, et al.Pageof 6